In order to raise biological comprehensibility and therapeutic efficiency of altan in treatment of ulcerative colitis (UC) scientists of UkrPA have developed altan tablets coated with eneterosoluble coat. Taking into consideration that destructive ulcerative lesion of large intestine develops on the basis of inflammatory processes often concomitant with spasm of intestine smooth muscles, aggravating the pathology progress, the objective of our survey included the study of anti-inflammatory properties of enterosoluble altan tablets (EAT) and their action on motor activity of gastrointestinal tract. As stabilization of cellular membranes may serve as an alternative mechanism of anti-inflammatory effect, membrane stabilizing action of EAT was studied. Anti-inflammatory activity of EAT as studied on the model of carrageen edema in rats. Its action on motor activity of gastrointestinal tract was studied using the method described by Sticknay. For studying the membrane-stabilizing action the method of spontaneous hemolysis by Yager was used. The study had demonstrated that EAT in dose 1 mg/kg shows expressed anti-inflammatory properties at the level of control preparation Voltaren in dose 8 mg/kg. Maximal anti-exudative activity of altan was marked within 2nd hour of inflammatory reaction (64.86%). The experiment had demonstrated the capability of EAT in dose 1 mg/kg to confidentially inhibit motor activity of gastrointestinal tract in mice, which fact indirectly proves a spasmolytic effect in correspondence with myotropic spasmolytic effect of ellagotannins described in literature. The dependence of membrane-stabilizing activity on EAT dose had been ascertained. Most expressed activity is typical for dose 1 mg/kg (82.63%). In doses 0.5 and 2.5 mg/kg membrane-stabilizing activity remained at the same level (68%). With dose increase up to 5 mg/kg preparation activity reduced (10.23%), which fact may be explained by pro-oxidant properties of vegetal polyphenols. Thus, the ascertained anti-inflammatory, membrane-stabilizing and spasmolytic properties of EAT may provide pathogenetic therapy of ulcerative and catarrhal colitis. The results of pharmacological survey make it possible to state that EAT is a promising drug for therapy of ulcerative colitis.